Floatz logo

LENALIDOMIDE

Primary Mediastinal Large B-Cell Lymphoma

David Bond, MDSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

80 Active assets in the Primary Mediastinal Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Ifosfamide
David Bond, MD
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB
DOXORUBICIN
University of Washington
Phase 4BBB
(+)-VINCRISTINE
Sun Yat-sen University
Phase 4BBB
Axicabtagene Ciloleucel
AIDS Malignancy Consortium
Phase 2BB

View all 50 →

Same molecule, other indications

LENALIDOMIDE is also rated in:

adult T-cell leukemia/lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
plasma cell neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →